EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...
Bristol Myers Squibb saw a 0.79% gain, closing at $60.28, while the broader market struggled, with the S&P 500 losing 0.91%.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
William Blair raised their Q3 2026 earnings per share estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the ...
Bristol-Myers Squibb (BMY) is ranked 5th among the best pharma stocks to buy according to hedge funds. The company boasts a ...
Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...